Romanian drug producer Antibiotice ended the first quarter with sales revenues of RON 60.5 million (EUR 13.4 million), up 2 percent year-on-year, and a net profit of RON 5.2 million (EUR 1.1 million), slightly up from the one posted the year before.

During this period, Antibiotics launched eight new products, and, in order to support this year’s sales, the company obtained 13 license renewals for products on the local market and 22 marketing authorizations for international markets.

“This sets the premises for growth in sales revenues, with good prospects of achieving the proposed turnover for 2014, of RON 340 million (EUR 75.5 million), of which exports of RON 95 million (EUR 21.1 million), up 7 percent against 2013,” reads the company’s quarterly report.

In the first three months, the company employed 15 people. Its main shareholders are the Romanian Health Ministry, with a 53 percent stake, and investment company SIF Oltenia, with 11.5 percent.

Irina Popescu, irina.popescu@romania-insider.com